Back to top

Image: Bigstock

Company News For Nov 26, 2019

Read MoreHide Full Article
  • Shares of Aquestive Therapeutics, Inc. (AQST - Free Report) gained 17.3% after the specialty pharmaceutical company received the FDA approval for EXSERVAN for the treatment of amyotrphic lateral sclerosis.
  • Shares of Intercept Pharmaceuticals, Inc. rose 8.4% after the FDA accepted Intercept’s New Drug Application for obeticholic acid for the treatment of Liver Fibrosis.
  • Shares of CymaBay Therapeutics, Inc. declined 76% after the clinical-stage biopharmaceutical company halted the clinical development of Seladelpar.
  • Shares of Surface Oncology, Inc. lost 21% after clinical-stage immuno-oncology company reported a $25 million debt financing from K2 HealthVentures.

See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Aquestive Therapeutics, Inc. (AQST) - free report >>

Published in